Zimberelimab
- Generic Name
- Zimberelimab
- Drug Type
- Biotech
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Androgen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Cancer, Castration-Resistant
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04381832
- Locations
- 🇺🇸
Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸The Oncology Institute of Hope & Innovation, Cerritos, California, United States
🇺🇸The University of California, Los Angeles, Encino, California, United States
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- Conditions
- Squamous Non Small Cell Lung CancerNon Small Cell Lung CancerLung CancerNonsquamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04262856
- Locations
- 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇨🇳Chi Mei Hospital, Tainan City, Taiwan
🇰🇷Chungbuk National University Hospital (CBNUH), Cheongju, Korea, Republic of
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04104672
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04087018
- Locations
- 🇺🇸
Saint Francis Cancer Center, Greenville, South Carolina, United States
🇺🇸Christiana Care Health System - Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT03972722
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
- Conditions
- Non Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of LungSensitizing EGFR Gene Mutation
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT03846310
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
🇰🇷Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 293
- Registration Number
- NCT03713905
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China
Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT03655483
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
- Conditions
- Solid Tumor, Unspecified, Adult
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03628677
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Tweed Hospital, Tweed Heads, New South Wales, Australia
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
- Conditions
- Non-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckBreast CancerColorectal CancerMelanomaBladder CancerOvarian CancerEndometrial CancerMerkel Cell CarcinomaGastroEsophageal Cancer
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03629756
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇦🇺Cabrini Health Limited, Malvern, Australia
🇺🇸Scottsdale Healthcare Hospitals dba HonorHealth, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.